This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
by Zacks Equity Research
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
Illumina, Broad Institute Partner on Secondary Genomic Analysis
by Zacks Equity Research
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $300.15 in the latest trading session, marking a +1.65% move from the prior day.
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
by Zacks Equity Research
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
Top Research Reports for Target, Illumina & T-Mobile US
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS).
Illumina (ILMN) Stock Moves 0.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $305.20, marking a +0.72% move from the previous day.
Illumina (ILMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $300.91, moving +1.14% from the previous trading session.
Illumina Banks on New Product Suite Despite Margin Woes
by Zacks Equity Research
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Probability 101: How Not to Be a Sucker
by Kevin Cook
We need science and math -- and STEM-savvy minds -- more than ever to help us inform decision making.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $271.71, marking a -0.17% move from the previous day.
ETFs to Gain From the Booming Genomics Market
by Sweta Jaiswal, FRM
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $281.62 in the latest trading session, marking a -1.19% move from the prior day.
Why Is Illumina (ILMN) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
What to Expect from Illumina Earnings After Preliminary Results Tanked ILMN Stock
by Zachary Stutler
Illumina is set to report its Q2 earnings on Monday, July 29 and investors are waiting to see if there is anything that might help the stock recover from its recent fall.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
The NASA of biotech just hit a growth speed-bump on its way to helping the world explore ancestry and disease
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $298.28, marking a +1.73% move from the previous day.